Quizartinib: all 38 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingNCT07478991Phase 3
• Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionRecruitingNCT06824168Phase 2
• Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaRecruitingNCT06769490Phase 1
• Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentRecruitingNCT06740799Phase 1
• CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsRecruitingNCT06262438Phase 2
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingNCT05735184Phase 1
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
• Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04047641Phase 1/2
• Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingNCT03661307Phase 1/2
• A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy SubjectsCompletedNCT04796831Phase 1Results posted
• A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic ImpairmentCompletedNCT04473664Phase 1Results posted
• A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy ParticipantsCompletedNCT04459598Phase 1Results posted
• A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy ParticipantsCompletedNCT04459585Early Phase 1Results posted
• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaTerminatedNCT04209725Phase 2Results posted
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03735875Phase 1/2Results posted
• Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)TerminatedNCT03552029Phase 1Results posted
• Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) MutationCompletedNCT02984995Phase 2Results posted
• Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02834390Phase 1Results posted
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)CompletedNCT02668653Phase 3Results posted
• (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD PositiveCompletedNCT02039726Phase 3Results posted
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01892371Phase 1/2Results posted
• Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01565668Phase 2Results posted
• A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 StatusCompletedNCT00462761Phase 1Results posted
• A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart RateCompletedNCT06772246Phase 1
• Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy SubjectsCompletedNCT06740825Phase 1
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLActive, not recruitingNCT06578247Phase 3
• Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AMLWithdrawnNCT04676243Phase 3
• Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingNCT04493138Phase 1/2
• Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeActive, not recruitingNCT04128748Phase 1/2
• A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
• Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)CompletedNCT04107727Phase 2
• Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodActive, not recruitingNCT03793478Phase 1/2
• Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT03723681Phase 1
• Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITDStatus unknownNCT03135054Phase 2
• Phase 1 Study of QuizartinibCompletedNCT02675478Phase 1
• A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)CompletedNCT01468467Phase 1
• A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01390337Phase 1
• A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.CompletedNCT01236144Phase 1/2

← Quizartinib overview